10 results about "Integrin receptors" patented technology

This invention provides a linear polypeptide and its application in cosmetics, belonging to the field of active molecule development technology. The polypeptide provided by this invention has a higher binding affinity to integrin receptors, significantly promoting fibroblast proliferation, increasing the content of elastin and type III collagen in the skin, and effectively scavenging DPPH free radicals and reducing reactive oxygen species levels. This polypeptide can be widely used in the preparation of cosmetics or topical skin formulations with anti-aging, antioxidant, and skin-repair promoting functions. It features high activity, good stability, and excellent safety, making it suitable as an active ingredient in functional skincare products.

The embodiment of the invention discloses recombinant XVII humanized collagen and a preparation method thereof, relates to the technical field of recombinant protein, and aims to solve the technical problem of low preparation efficiency of existing XVII type collagen. The preparation method of the recombinant XVII humanized collagen comprises the following steps: obtaining an amino acid sequence containing an integrin receptor site "RGD" and a binding site "KGHK"; based on the amino acid sequence, obtaining recombinant humanized collagen protein granules; the method comprises the following steps: obtaining recombinant lysine hydroxylase gene plasmids on the basis of a human gene LH2; and obtaining the recombinant XVII humanized collagen on the basis of the recombinant humanized collagen protein plasmid and the recombinant lysine hydroxylase gene plasmid.

The invention discloses a polypeptide oligonucleotide coupling conjugate capable of being combined with an integrin alpha v beta 6 protein receptor, and further discloses a composition containing the oligonucleotide conjugate and application of the composition, and the conjugate can be used for preparing a medicine, a medicine, a medicine carrier and the like. The medicine can be used for preventing and / or treating diseases related to the medicine delivered through the mediation of the integrin receptor alpha v beta 6 protein receptor.

Provided are a recombinant human fibronectin (FN) having a complex function of soothing, a preparation method therefor, and the use thereof. Said recombinant human fibronectin has an amino acid sequence shown as SEQ ID NO.1. By adding a hyaluronic acid interaction segment of human fibronectin while retaining main segments of human fibronectin cell adhesion and integrin receptor interaction, and linking the two domains by means of a flexible "linker" amino acid sequence GGS, the recombinant human FN protein having the complex function is constructed. While possessing core characteristics of traditional recombinant fibronectins, the present recombinant human fibronectin also exhibits an effect of soothing cell irritations. Therefore, the prepared recombinant human fibronectin is expected to exhibit a good effect in soothing skin irritation in the field of functional active skincare products.

The application relates to an integrin receptor targeting polypeptide derivative and molecular probe and application. The integrin receptor targeting polypeptide derivative has a structure shown in formula I. The novel polypeptide derivative constructed by the application has the function of simultaneously coupling multiple imaging molecules, and can be simultaneously used for preoperative diagnosis and intraoperative guidance of multiple imaging methods. The research result can provide a new idea for further development of molecular imaging, and increase the range of clinical application of molecular imaging.

Described herein are conjugates targeting the ανβ6 integrin receptor and pharmaceutical compositions (e.g., radiopharmaceutical compositions) comprising said conjugates. The subject conjugates and compositions are useful for the treatment of a disease or disorder associated with ανβ6 integrin receptor. In some embodiments, a conjugate described herein has a structure of the following formula:, wherein values for the variables are as described herein.

The invention discloses an X-ray response type neutrophile granulocyte loaded nanometer vitepofen and an application thereof. According to the invention, a solvent-anti-solvent method is combined with a hydrothermal method to prepare the nano vitepofen. The nanometer vitepofen can adsorb part of protein in plasma in vivo, and a'protein crown 'layer is formed on the surfaces of particles. The adsorbed complement C3 can be specifically combined with a CR3 receptor on the surface of the activated neutrophil, and proteins such as fibrinogen and the like can be combined with an integrin receptor on the surface of the neutrophil, so that the nano vitepofen is delivered to a tumor focus in a targeted manner by utilizing the inflammatory chemotactic characteristic of the neutrophil. Moreover, the nano vitepofen has an X-ray response characteristic, and can generate active oxygen in tumor cells under X-ray irradiation and induce the tumor cells to generate immunogenic death, so that the anti-tumor immune response of an organism is triggered, the radiotherapy curative effect is enhanced, and the radiotherapy sensitization is realized.

The invention relates to a polypeptide coupling compound with high affinity to an integrin receptor (alpha V beta 3) and pharmaceutically acceptable salts thereof, a pharmaceutical composition containing the polypeptide coupling compound and the pharmaceutically acceptable salts, and application of the pharmaceutical coupling compound and the pharmaceutical composition in preparation of drugs for preventing and / or treating alpha V beta 3 overexpression diseases.

Provided herein are α4β1 / 7 integrin receptor ligand-containing compounds, methods of delivering said compounds, and methods of treating diseases, disorders, and symptoms (e.g., central nervous system diseases, disorders, and symptoms) in a subject using said compounds.

A pharmaceutical composition comprises a drug-carrier system having a small-molecule drug of low water solubility such as one or more small molecule integrin agonist adjuvants in a substantially non-aqueous carrier composition that comprises at least one phospholipid, at least one neutral lipid, and at least one pharmaceutically acceptable solubilizing agent. The drug-carrier system, when mixed with an aqueous phase, typically forms a non-gelling, substantially non-transparent liquid dispersion. The composition is suitable for administration by a suitable route, e.g., orally, to a subject in need thereof.